Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West

被引:7
|
作者
Lee, V. H. F. [1 ,2 ]
Seong, J. [3 ]
Yoon, S. M. [4 ]
Wong, T. C. L. [5 ]
Wang, B. [2 ]
Zhang, J. L. [2 ]
Chiang, C. L. [1 ,2 ]
Ho, P. P. Y. [1 ]
Dawson, L. A. [6 ,7 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Shenzhen Hosp, Clin Oncol Ctr, Shenzhen, Peoples R China
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Radiat Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Liver Ctr, Asan Med Ctr,Dept Radiat Oncol, Seoul, South Korea
[5] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Peoples R China
[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[7] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
关键词
Bridging therapy; hepatocellular carcinoma; targeted therapy; transarterial chemoembolisation; transarterial radioembolisation; STEREOTACTIC BODY RADIOTHERAPY; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; PORTAL-VEIN-THROMBOSIS; RADIATION-THERAPY; DOUBLE-BLIND; PHASE-III; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION;
D O I
10.1016/j.clon.2019.06.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:560 / 569
页数:10
相关论文
共 50 条
  • [21] IBD - differences between east and west
    Fedorak, Richard N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 43 - 43
  • [22] Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West
    Yen, Yi-Hao
    Cheng, Yu-Fan
    Wang, Jing-Houng
    Lin, Chih-Che
    Chen, Yen-Yang
    Yong, Chee-Chien
    Liu, Yueh-Wei
    Cheng, Jen-Yu
    Chen, Chien-Hung
    Hu, Tsung-Hui
    PLOS ONE, 2020, 15 (03):
  • [23] Changing faces of hepatocellular carcinoma: East vs West
    Huo, Teh-Ia
    Ho, Shu-Yein
    Liu, Po-Hong
    LIVER INTERNATIONAL, 2021, 41 (06) : 1430 - 1431
  • [24] Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion
    Lee, Ching-Hsin
    Chen, An-Hsin
    Hung, Sheng-Ping
    Hsieh, Cheng-En
    Tseng, Jeng-Hwei
    Chen, Po-Jui
    Cheng, Jen-Yu
    Chang, Joseph Tung-Chieh
    Chan, Kun-Ming
    Lin, Shi-Ming
    Lin, Chen-Chun
    Chen, Wei-Ting
    Chen, Wan-Yu
    Huang, Bing-Shen
    CANCERS, 2022, 14 (07)
  • [25] Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
    Feun, Lynn G.
    Li, Ying-Ying
    Wangpaichitr, Medhi
    Jones, Patricia Denise
    Richman, Stephen P.
    Madrazo, Beatrice
    Kwon, Deukwoo
    Martin, Paul
    Hosein, Peter Joel
    Savaraj, Niramol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
    M Schmidinger
    C Wenzel
    G J Locker
    F Muehlbacher
    R Steininger
    M Gnant
    R Crevenna
    A C Budinsky
    British Journal of Cancer, 2001, 85 : 1850 - 1852
  • [27] Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
    Schmidinger, M
    Wenzel, C
    Locker, GJ
    Muehlbacher, F
    Steininger, R
    Gnant, M
    Crevenna, R
    Budinsky, AC
    Steger, GG
    BRITISH JOURNAL OF CANCER, 2001, 85 (12) : 1850 - 1852
  • [28] Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma
    Moroni, Marco
    Zanlorenzi, Laura
    FUTURE ONCOLOGY, 2013, 9 (08) : 1231 - 1237
  • [29] Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
    Sun W.
    Cabrera R.
    Journal of Gastrointestinal Cancer, 2018, 49 (2) : 107 - 115
  • [30] ADVANCED UNRESECTABLE HEPATOCELLULAR-CARCINOMA (HCC) - IMPROVED RESPONSES AND SURVIVAL
    CARR, BI
    SELBY, R
    MADARIAGA, J
    IWATSUKI, S
    STARZL, TE
    HEPATOLOGY, 1992, 16 (02) : 521 - 521